| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 trial initiation example | Phase 1/2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1/2 trial initiation example | Phase 1/2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1/2 trial initiation example | Phase 1/2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Crescent Biopharma, Inc.$14.75
-0.36 (-2.38%)
C 42Pipeline Score Fair Value Biotech · Clinical
Market Cap
500.71 M
EPS
-15.35
P/E Ratio
-1.18 $
Value Trade
2.56 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.04 M
R&D Expenses
17.90 M
Operating CF
-8.94 M
Total Assets
199.13 M
Total Liabilities
15.28 M
Equity
183.85 M
D/E Ratio
12,345
-1.64 %
Week
-16.77 %
1 Month
-40.22 %
3 Month
-48.66 %
6 Month
-97.34 %
5 Year
-98.73 %
All Time
Cash Data
Cash Position
189.16 M
Monthly Burn
2.98 M
Runway
61.1 mo
Burn Trend
SEC Filing
Apr 29, 2026
Overview
Volume
318.21 K
52 Week Range
8.72 - 28.77
% held by Insiders
22.66 %
% held by Institutions
79.31 %
Enterprise Value
293.16 M
Total Shares
27.56 M
Short %
20.28 %
Float Shares
18.11 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Crescent Biopharma, Inc.
297Total events
10Upcoming
58Tier-1 (high impact)
2013 – 2034Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | CR-002 | IND Submission | IND | — | – | – | – |
2026-06-30 | CR-002 | IND Submission | IND | — | – | – | – |
2026-06-30 | CR-002 | IND Submission | IND | — | – | – | – |
Drug Pipeline Intelligence
C42
Pipeline Score $376M
Pipeline ValueFair Value
Valuation Signal1
Drugs Scored0.8x
rNPV / MCap Top 62%
Micro Cap (rank 348 of 912)
Percentile RankCrescent Biopharma, Inc. carries a moderate pipeline score (42/100), with $941M risk-adjusted pipeline value, led by -001 in Locally Advanced / Metastatic Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -001 Small molecule | Locally Advanced / Metastatic Solid Tumors | Phase 1 | NCT07335497 | 5% | $941M | RECRUITING | 290 | VERY_FAST | D (37) | Feb 1, 2029 | MODERATE_RISK | LOW Jul 13, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
uproleselan | acute myeloid leukemia | Phase 2/3 | 2024-10-29 | did not show a statistically significant improvement in event free survival (EFS) for patients receiving uproleselan in combination with 7+3 chemotherapy versus chemotherapy alone Read More | GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint ROCKVILLE, Md.--(BUSINESS WIRE) Read More | |
uproleselan | acute myeloid leukemia | Phase 2/3 | 2024-10-29 | did not show a statistically significant improvement in event free survival (EFS) for patients receiving uproleselan in combination with 7+3 chemotherapy versus chemotherapy alone Read More | GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint ROCKVILLE, Md.--(BUSINESS WIRE) Read More | |
uproleselan | acute myeloid leukemia | Phase 2/3 | 2024-10-29 | did not show a statistically significant improvement in event free survival (EFS) for patients receiving uproleselan in combination with 7+3 chemotherapy versus chemotherapy alone Read More | GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint ROCKVILLE, Md.--(BUSINESS WIRE) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CBIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CBIO▼ -2.4%today
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Crescent Biopharma has completed its public offering of 9,387,896 ordinary shares, raising about $143.7 million. The offering included a full exercise of the underwriters' option to purchase additional shares. The shares were sold at $14.50 each, and the company aims to leverage the funds to advance its oncology pipeline.
Read more →CBIO▼ -2.4%today
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Crescent Biopharma has announced the pricing of its public offering, which includes 8,094,793 ordinary shares and pre-funded warrants. The shares are priced at $14.50 each, with gross proceeds estimated at $125 million. The offering is set to close on July 16, 2026, pending customary closing conditions. Jefferies and other firms are managing the offering.
Read more →CBIOCrescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Crescent Biopharma has announced a proposed public offering of ordinary shares and pre-funded warrants. The offering is intended to support the company's development of cancer therapies and includes a 30-day option for underwriters to purchase additional shares. The completion of the offering is subject to market conditions and other factors.
Read more →CBIOCrescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma, Inc. has announced the approval of equity inducement awards granting options to purchase 23,550 shares to two non-executive employees. This decision was made by the independent Compensation Committee and is part of the company's efforts to attract talent under its 2025 Employment Inducement Incentive Award Plan. The options have a 10-year term with an exercise price of $17.57 and will vest over time based on the employees' continued service at the company. Crescent Biopharma aims to leverage these awards to foster its clinical-stage oncology programs.
Read more →CBIO▲ +5.7%on this news
Crescent Biopharma to Present at June 2026 Investor Conferences
Crescent Biopharma, a clinical-stage biotechnology firm, will present at several investor conferences in June 2026. The company focuses on developing advanced therapies for cancer, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates. Live webcasts of the presentations will be available on their website.
Read more →CBIO▼ -13.8%on this newsshared move
Crescent Biopharma to Present at June Investor Conferences
Crescent Biopharma, a clinical-stage biotechnology company, announced its participation in two investor conferences in June 2026. The presentations will take place at the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. Live webcasts will be available, showcasing the company's commitment to advancing cancer therapies.
Read more →CBIOCrescent Biopharma Announces Grants of Inducement Awards - May 29, 2026
Crescent Biopharma announced the approval of equity inducement awards for two non-executive employees, granting options to purchase 16,950 shares. The options, with a 10-year term and an exercise price of $21.47, are part of the company's strategy to attract and retain talent. This move aligns with Crescent's commitment to advancing cancer therapies.
Read more →CBIOCrescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Crescent Biopharma announced the presentation of a trial in progress for its ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, at the 2026 ASCO Annual Meeting. The Phase 1/2 trial is evaluating CR-001 in various solid tumors, with enrollment ongoing. Initial data readouts are anticipated in early 2027, aiming to assess the drug's safety and preliminary antitumor activity.
Read more →CBIO▲ +6.2%on this news
Crescent Biopharma Announces Grants of Inducement Awards - May 12, 2026
Crescent Biopharma, a clinical-stage biotechnology company, announced the approval of equity inducement awards for five non-executive employees. The awards consist of options to purchase 129,075 shares at an exercise price of $18.52, with a 10-year term. This move is part of the company's strategy to attract talent and advance its oncology pipeline.
Read more →CBIOCrescent Biopharma to Present at May Investor Conferences
Crescent Biopharma, a clinical-stage biotechnology company, announced its participation in several investor conferences throughout May 2026. The presentations include a fireside chat at the BofA Securities Healthcare Conference and other virtual events. The company aims to showcase its innovative cancer therapies, including a PD-1 x VEGF bispecific antibody.
Read more →CBIO▼ -12.6%on this news· ran to -25% by day 3
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma reported its first quarter financial results for 2026, highlighting significant advancements in its clinical pipeline. The company is actively conducting global trials for its PD-1 x VEGF bispecific antibody, CR-001, alongside other therapeutic candidates including CR-002 and CR-003. Key milestones are anticipated in the coming years, including proof-of-concept clinical data starting in Q1 2027. Despite an increase in net losses and expenses, Crescent's robust cash position aims to facilitate continued development and operational stability.
Read more →CBIOCrescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Crescent Biopharma reported its financial results for Q4 and full year 2025, highlighting a transformative year with the launch of the ASCEND Phase 1/2 trial for CR-001. The company has established a partnership with Kelun-Biotech to enhance its pipeline and is well-funded through a recent $185 million private placement. Despite a significant net loss, the company anticipates multiple clinical data readouts starting in Q1 2027.
Read more →CBIOCrescent Biopharma to Present at March Investor Conferences
Crescent Biopharma, a clinical-stage biotechnology company, will present at several investor conferences in March 2026. The company focuses on developing innovative cancer therapies, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates. Live webcasts of the presentations will be available on their website.
Read more →CBIOCrescent Biopharma to Present at March 2026 Investor Conferences
Crescent Biopharma, a clinical-stage biotechnology firm, announced its participation in investor conferences scheduled for March 2026. The company aims to showcase its innovative cancer therapies, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates. Live webcasts of the presentations will be available on their website.
Read more →CBIOCrescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
Crescent Biopharma has initiated its ASCEND Phase 1/2 clinical trial, dosing the first patient with CR-001, a bispecific antibody targeting PD-1 and VEGF for advanced solid tumors. The trial will evaluate CR-001's safety and efficacy across various solid tumor types, with proof-of-concept data expected in early 2027. This trial is part of a broader strategy to enhance cancer treatment options.
Read more →CBIOCrescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Crescent Biopharma, a clinical-stage biotechnology firm, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on February 12, 2026. The event will feature a fireside chat with management, highlighting the company's commitment to developing advanced cancer therapies. A live webcast will be available, along with a replay for 90 days post-event.
Read more →CBIOCrescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
Crescent Biopharma has received regulatory clearances for its IND applications for CR-001 and CR-003, aimed at treating solid tumors. The ASCEND trial for CR-001 is set to begin in the first quarter of 2026, with proof-of-concept data expected in early 2027. The company is also collaborating with Kelun-Biotech for further development of these therapies.
Read more →CBIODocument Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integri
Kelun-Biotech and Crescent Biopharma have announced a strategic partnership focused on developing and commercializing novel oncology therapeutics, specifically the bispecific antibody CR-001 and the antibody-drug conjugate SKB105. Both candidates are scheduled to begin Phase 1/2 clinical trials in early 2026. Under the terms of the collaboration, Kelun-Biotech and Crescent share exclusive rights in different markets, enhancing their respective positions in the oncology sector. The partnership is poised to leverage synergies in clinical development and commercialization, which could lead to transformative treatments for solid tumors.
Read more →CBIOCrescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
Crescent Biopharma has announced a strategic partnership with Kelun-Biotech, focusing on the development of next-generation oncology therapeutics. This partnership is set to accelerate the advancement of their pipeline, particularly with the bispecific antibody CR-001 and several antibody-drug conjugates. The company also revealed a $185 million private placement, which will finance upcoming clinical trials and provide a cash runway into 2028. With the first clinical trials expected to commence in 2026, the partnership aims to generate significant clinical data by the end of 2027.
Read more →CBIO▲ +5.4%on this news
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Crescent Biopharma reported its Q3 2025 financial results, highlighting progress in its cancer therapy pipeline. The company is set to submit an IND for CR-001, a PD-1 x VEGF bispecific antibody, by Q4 2025, with a global Phase 1 trial starting in early 2026. Additionally, they plan to submit an IND for CR-002 by mid-2026. Despite a net loss of $24.6 million, Crescent maintains a robust cash position.
Read more →CBIOCrescent Biopharma to Present at November Investor Conferences
Crescent Biopharma, a biotechnology firm focused on cancer therapies, announced its participation in several investor conferences in November. The company aims to showcase its innovative pipeline, which includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates. Live webcasts of the presentations will be available on their website.
Read more →CBIOCrescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Crescent Biopharma announced that preclinical data for CR-001, a PD-1 x VEGF bispecific antibody, will be presented at the SITC 40th Annual Meeting. The data highlights CR-001's cooperative pharmacology and significant anti-tumor activity. The company plans to initiate a global Phase 1 trial in patients with solid tumors in early 2026.
Read more →CBIOCrescent Biopharma to Present at September Investor Conferences
Crescent Biopharma, Inc. has announced its participation in two significant investor conferences scheduled for September 2025. Management will present at the Cantor Global Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference, aiming to raise awareness of its oncology initiatives. The company is focused on delivering next-generation therapies for cancer patients and offers a diverse pipeline that includes innovative treatments. Webcasts of the presentations will be available on their website for investors and interested parties.
Read more →CBIOCrescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Crescent Biopharma announced its financial results for Q2 2025, highlighting the completion of its merger with GlycoMimetics and a successful $200 million financing round. The company is focused on its lead program, CR-001, a PD-1 x VEGF bispecific antibody, with an IND submission expected by the end of 2025 and proof-of-concept data projected for 2026. Despite a net loss of $21.8 million this quarter, the organization has strengthened its leadership team with experienced individuals in oncology and aims to expedite development in solid tumor therapeutics. The cash position appears stable, supporting operations through 2027.
Read more →CBIOCrescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
Crescent Biopharma has appointed Dr. Jan Pinkas as Chief Scientific Officer, enhancing its leadership in oncology drug development. Dr. Pinkas brings over two decades of experience and will play a crucial role in advancing the company's pipeline, including the upcoming Phase 1 trial of CR-001. The company is focused on innovative therapies for solid tumors.
Read more →CBIO▲ +105.9%on this news
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
Crescent Biopharma has successfully completed its merger with GlycoMimetics, with shares now trading under the ticker 'CBIO'. The company raised $200 million in a private placement to support its operations and pipeline development. Crescent aims to submit an IND application for its lead program, CR-001, by the end of 2025, with clinical data expected in 2026.
Read more →CBIO▲ +105.9%on this newsshared move
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals - GlycoMimetics Board of Directors approves 1-for-100 reverse stock split - ROCKVILLE, Md.
GlycoMimetics, Inc. announced that its stockholders have approved the merger with Crescent Biopharma, along with associated proposals, during a special meeting on June 5, 2025. The board also sanctioned a 1-for-100 reverse stock split, which is set to take effect prior to the expected trading of the combined company under the new name, Crescent Biopharma, Inc. The merger aims to enhance operational capabilities and market presence, though it introduces certain financial restructuring risks that may affect investor sentiment.
Read more →CBIO▲ +105.9%on this newsshared move
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
Crescent Biopharma, a private biotechnology firm, will present at the Jefferies Global Healthcare Conference on June 5, 2025. The company focuses on developing precision-engineered molecules for solid tumors. Following an acquisition agreement with GlycoMimetics, the combined entity will operate under the Crescent Biopharma name and enhance its therapeutic offerings.
Read more →CBIO▲ +105.9%on this newsshared move
Crescent Biopharma Appoints David Lubner to Board of Directors
Crescent Biopharma has appointed David Lubner to its board of directors, bringing 30 years of finance and operations experience. His expertise is expected to support the growth of Crescent's programs, including a bispecific antibody targeting solid tumors. The company is also preparing for an IND application submission for its lead program, CR-001, by late 2025.
Read more →CBIO▲ +105.9%on this newsshared move
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
Crescent Biopharma has announced the appointment of Joshua Brumm as CEO, alongside a new leadership team including Jonathan McNeill, M.D., as President and COO, and Ellie Im, M.D., as Chief Medical Officer. The team brings extensive experience in oncology and aims to advance the company's pipeline, including a bispecific antibody program set for IND submission in late 2025.
Read more →CBIO▲ +105.9%on this newsshared move
Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Crescent Biopharma, a private biotechnology firm focused on treating solid tumors, will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025. This presentation will highlight the company's commitment to advancing their precision-engineered molecules. In October 2024, Crescent entered an acquisition agreement with GlycoMimetics, which will enhance its portfolio of biologics. The webcast of the presentation will be accessible live and archived for 90 days after the event.
Read more →CBIO▲ +105.9%on this newsshared move
January 2025 Crescent Biopharma Overview 2 Disclaimer This presentation is for informational purposes only and only a summary of certain information related to the Company . It does not purport to be complete and does no
Crescent Biopharma provided an overview of its operations and pipeline in a recent presentation. The company is focused on developing innovative therapies for solid tumors, with a pipeline that includes several promising candidates. Crescent is backed by significant financing expected to fund operations until 2027. The presentation includes disclaimers regarding forward-looking statements and the necessity for investors to conduct their own evaluations before making investment decisions.
Read more →CBIO▲ +105.9%on this newsshared move
November 2024 Crescent Biopharma Overview 2 Disclaimer This presentation is for informational purposes only and only a summary of certain information related to the Company . It does not purport to be complete and does n
Crescent Biopharma's November 2024 overview highlights its advancement in innovative cancer therapies, specifically targeting solid tumors through its proprietary drug programs like CR-001, CR-002, and CR-003. The company plans to leverage recent financing to support operations and development through 2027. Its focus on effective PD-1 x VEGF therapies aligns with an expanding market for cancer immunotherapy, potentially establishing Crescent as a key player in this field.
Read more →CBIO▲ +105.9%on this newsshared move
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint ROCKVILLE, Md.--(BUSINESS WIRE)
GlycoMimetics, Inc. announced that its Phase 2/3 study of uproleselan, conducted in partnership with the National Cancer Institute, did not achieve its primary endpoint of improving event free survival in older adults with newly diagnosed acute myeloid leukemia. The study compared the treatment's efficacy when combined with standard chemotherapy versus chemotherapy alone. In light of these results, further analysis will be conducted to explore potential efficacy signals in specific patient populations. The findings are expected to be presented at a future medical conference.
Read more →CBIO▲ +105.9%on this newsshared move
About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company's scie
GlycoMimetics, Inc. has announced a strategic review and corporate restructuring plan to extend its cash runway and assess potential strategic alternatives. The company is currently seeking to enhance shareholder value while focusing on advancing its drug candidates, particularly uproleselan and GMI-1687. As part of these efforts, GlycoMimetics has engaged Lucid Capital Markets as a strategic advisor. Notably, uproleselan is being studied in a Phase 2/3 clinical trial for newly diagnosed acute myeloid leukemia (AML) patients, aiming to address significant unmet medical needs in oncology.
Read more →CBIO▲ +105.9%on this newsshared move
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Company exploring path forward for uproleselan in multiple AML se
GlycoMimetics has announced comprehensive results from a pivotal Phase 3 study of uproleselan, an investigational E-selectin antagonist, for patients with relapsed or refractory acute myeloid leukemia (AML). Despite not achieving statistically significant differences in overall survival between uproleselan and placebo, the drug demonstrated a potential for clinically meaningful benefits, particularly in patients with primary refractory disease. The company plans to engage with regulatory agencies to explore the next steps for uproleselan as a treatment option for AML. The study involved 388 patients in nine countries and emphasized the ongoing need for new therapies in this challenging medical area.
Read more →CBIO▲ +105.9%on this newsshared move
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overa
GlycoMimetics announced that its Phase 3 study of uproleselan combined with chemotherapy in patients with relapsed/refractory acute myeloid leukemia did not meet the primary endpoint of improved overall survival. In the trial, patients receiving uproleselan had a median overall survival of 13 months, which was only slightly better than the 12.3 months reported in the placebo group. The company plans to conduct a comprehensive data analysis in collaboration with experts and will share findings at an upcoming medical meeting. Despite the setback, GlycoMimetics has previously received designations hinting at the drug's potential.
Read more →CBIO▲ +105.9%on this newsshared move
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be repor
GlycoMimetics, Inc. reported its fourth quarter and full year 2023 financial results, highlighting a net loss of $36.9 million. The company is preparing to release topline results from its pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML) in Q2, which shows promise in establishing a new standard of care. Furthermore, GlycoMimetics announced their agreement with the ASH RC for GMI-1687, aimed at treating sickle cell disease, and confirmed ongoing commitment to advancing their pipeline of therapies.
Read more →CBIO▲ +105.9%on this newsshared move
x2022; To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of Glyco
GlycoMimetics presented preliminary data for its novel drug GMI-1687 at ASH 2022/2023, highlighting its potential as a treatment for sickle cell disease vaso-occlusive crises and its designation as a breakthrough therapy. The company emphasized its innovative carbohydrate signaling inhibition approach and its ongoing strategies in rare diseases. Key leadership appointments have been made to enhance operational capabilities. The drug's first-in-class status suggests a substantial impact on treatment paradigms within its targeted indications.
Read more →CBIO▲ +105.9%on this newsshared move
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) on track to be reported by
GlycoMimetics reported its financial results for the third quarter of 2023, highlighting a net loss of $9.2 million and cash equivalents of $49.4 million as of September 30, 2023. The CEO expressed enthusiasm for the upcoming pivotal Phase 3 study results of uproleselan in relapsed/refractory AML, which are expected by the end of Q2 2024. The company is also advancing its GMI-1687 study, designed for treating sickle cell disease, further supporting its goal of becoming a commercial-stage biotech firm.
Read more →CBIOGlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) expected by end of Q2 202
GlycoMimetics, Inc. has reported its financial results for the second quarter of 2023, showcasing cash reserves of $58.0 million. The company anticipates topline results for its pivotal Phase 3 study of uproleselan in relapsed/refractory Acute Myeloid Leukemia (AML) by the end of Q2 2024, following a time-based analysis addition to the study. GlycoMimetics also received favorable FDA designations for uproleselan and plans to initiate a Phase 1a study for GMI-1687, expanding its clinical pipeline for potential therapies in cancer and inflammatory diseases. However, the company has incurred significant operational losses during this period.
Read more →CBIOGlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 Pivotal Phase 3 study of uproleselan combined with cytarabine-based chemotherapy in relapsed/refractory (R/R) acute myeloid leukemia (AML) con
GlycoMimetics has reported its financial results and operational highlights for Q1 2023, indicating a strong cash position of $65 million. The company is focused on the Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML), having received Breakthrough Therapy designation. GlycoMimetics expressed optimism about the therapy's potential to enhance survival rates among R/R AML patients and anticipates completing the final trial analysis following critical survival events in the first half of 2024.
Read more →CBIOGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 Significant progress in strengthening leadership, raising capital, and preparing for final results of the uproleselan Phase 3 st
GlycoMimetics, Inc. reported its financial results for the fourth quarter and year-end of 2022, which included raising $28.7 million post year-end. The CEO highlighted progress in the company's leadership and the promising results of the Phase 3 trial for uproleselan, indicating a noteworthy median follow-up time of 25 months. Research and development expenses decreased to $28.4 million compared to the previous year. However, the company experienced significant financial losses, with total assets dropping markedly over the year.
Read more →CBIOxA9; 2021 GlycoMimetics, Inc. All rights reserved. Glycobiology-based therapeutics Transforming lives NASDAQ: GLYC March 2023 • To the extent that statements contained in this presentation are not descriptions of
GlycoMimetics is making strides in glycobiology-based therapeutics, particularly for sickle cell disease and fibrotic disorders. Their candidate GMI-1687 is a fast-acting small molecule aimed at reducing pain crises in sickle cell patients and has received FDA clearance for IND. The company’s broad early-stage pipeline includes novel therapies targeting Galectin-3 and aims to address significant unmet medical needs. Additionally, recent leadership hires will likely bolster their operational strategy in hemato-oncology treatments.
Read more →CBIOGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022 U.S. Food and Drug Administration (FDA) clears protocol amendment to conduct an interim utility analysis of pivotal Phase 3 study of uprolesel
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022 ROCKVILLE, Md.--(BUSINESS WIRE) - November 9, 2022-- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers
Read more →CBIOxA9;2021 GlycoMimetics, Inc. All rights reserved. Glycobiology-based therapeuticsTransforming livesOctober 2022 Corporate Presentation NASDAQ: GLYC •To the extent that statements contained in this presentation are
Wun, ASH 2020 October 2022181 Morikis et al, Frontiers in Immunology, April 2021, Vol. 12, Article 663886GMI-1687 leverages years of research to empower patients to take control of their disease Lessons LearnedGMI-1687 E-selectin drives acute VOC1-Fast-acting, small molecule inhi
Read more →CBIOGlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022 U.S. Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) application to study GMI-1687 in Sickle Cell Disease (SCD
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022 ROCKVILLE, Md.--(BUSINESS WIRE) - August 3, 2022-- GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the second quarter ended June 30, 2022. Cash and cash equi
Read more →CBIO▼ -5.8%on this news
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022 Mid-year 2023 projected for events trigger of the GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relaps
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022 ROCKVILLE, MD - April 28, 2022-- GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the first quarter ended March 31, 2022. Cash and cash equivalents at March 3
Read more →CBIO▲ +13.1%on this news
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021 Post year-end 2022 remains target for top-line data release of GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproles
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021 ROCKVILLE, MD -- March 3, 2022-- GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the fourth quarter and year ended December 31, 2021. Cash and
Read more →CBIOGLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR THIRD QUARTER 2021 Significant progress achieved for lead investigational drug candidate uproleselan: o Robust enrollment momentum in the quarter indicates immin
GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR THIRD QUARTER 2021 ROCKVILLE, MD, November 2, 2021 - GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended September 30, 2021 and highlighted recent events. Cash and cash equivale
Read more →CBIOGLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR SECOND QUARTER 2021 Completion of enrollment is expected by year-end 2021 for the Company-sponsored Phase 3 pivotal trial evaluating uproleselan in patients with
GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR SECOND QUARTER 2021 ROCKVILLE, MD, August 5, 2021-- GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended June 30, 2021 and highlighted recent events. Cash and cash equivalents at
Read more →CBIOG LYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR FIRST QUARTER 2021 GlycoMimetics continues to target year-end 2021 for completing enrollment of the Company-sponsored pivotal trial evaluating uproleselan in pa
GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR Rockville, MD - May 3, 2021 - GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2021 and highlighted recent company events. Cash and cash equivalents at March 31, 202
Read more →CBIOG LYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2020 Second half of 2021 remains the target for completion of enrollment of the GlycoMimetics-sponsored pivotal Phase 3 trial evalu
GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2020 Rockville, MD - March 2, 2021 - GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent C
Read more →CBIOGLYCOMIMETICS PROMOTES DR. ERIC FELDMAN TO CHIEF MEDICAL OFFICER Rockville, MD
GLYCOMIMETICS PROMOTES DR. ERIC FELDMAN TO CHIEF MEDICAL OFFICER Rockville, MD - February 23, 2021 - GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 201
Read more →CBIOG LYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR THIRD QUARTER 2020 Enrollment in the Company-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia
GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR ROCKVILLE, Md. - November 6, 2020 - GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and cash equivalents
Read more →CBIOG LYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR SECOND QUARTER 2020 Enrollment in the Company-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia
GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR ROCKVILLE, MD, July 31, 2020 -- GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the second quarter ended June 30, 2020, and highlighted recent company events. Cash and cash equivalents at June
Read more →CBIOGLYCOMIMETICS REPORTS OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR FIRST QUARTER 2020 · Entered into an exclusive collaboration and license agreement with Apollomics for development and commercialization of upro
GLYCOMIMETICS REPORTS OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR ROCKVILLE, MD, May 1, 2020 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents a
Read more →CBIOGLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR-END 2019 · Continued patient enrollment in both the Company-sponsored and NCI-sponsored Phase 3 clinical trials of uproleselan in ac
GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR-END 2019 ROCKVILLE, MD, February 28, 2020 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the year and fourth quarter ended December 31, 2019 and highlighted recent co
Read more →CBIOGLYCOMIMETICS AND APOLLOMICS Announce Exclusive Collaboration and License Agreement to Develop and Commercialize UPROLESELAN and GMI-1687 IN GREATER CHINA - GlycoMimetics to receive an upfront cash payment with eligibili
GLYCOMIMETICS AND APOLLOMICS Announce Exclusive Collaboration and License Agreement to Develop and Commercialize UPROLESELAN and GMI-1687 ROCKVILLE, MD, USA; FOSTER CITY, CA, USA and Hangzhou, China, January 6, 2020 GlycoMimetics, Inc. (NASDAQ: GLYC), a leader in the field of ap
Read more →CBIOGLYCOMIMETICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL DEVELOPMENTS · Advanced its Phase 3 program for uproleselan in acute myeloid leukemia (AML) through both Company-sponsored and NCI-sp
GLYCOMIMETICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL DEVELOPMENTS ROCKVILLE, MD, November 7, 2019 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended September 30, 2019 and highlighted recent business develo
Read more →CBIOGLYCOMIMETICS REPORTS TOP-LINE RESULTS FROM PFIZER'S PHASE 3 CLINICAL TRIAL EVALUATING RIVIPANSEL IN SICKLE CELL DISEASE ROCKVILLE, MD, aUGUST 2, 2019 – GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Pfizer Inc.
GLYCOMIMETICS REPORTS TOP-LINE RESULTS FROM PFIZER'S PHASE 3 CLINICAL TRIAL EVALUATING RIVIPANSEL IN SICKLE CELL DISEASE ROCKVILLE, MD, aUGUST 2, 2019 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 Rivipansel (GMI-1070):
Read more →CBIOGLYCOMIMETICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS · Announced completion of enrollment in Pfizer's Phase 3 clinical trial evaluating rivipansel, the Company's lead investi
GLYCOMIMETICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS ROCKVILLE, MD, August 1, 2019 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended June 30, 2019 and highlighted recent business achievements.
Read more →CBIOGLYCOMIMETICS REPORTS FIRST QUARTER 2019 RESULTS AND RECENT OPERATIONAL HIGHLIGHTS · Enrolled first patient in National Cancer Institute (NCI)-sponsored Phase 3 trial of uproleselan in older adults with previously u
GLYCOMIMETICS REPORTS FIRST QUARTER 2019 RESULTS AND RECENT OPERATIONAL HIGHLIGHTS ROCKVILLE, MD, MaY 2, 2019 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2019 and highlighted recent company achievements. Quarter-
Read more →CBIOGLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2018 RESULTS · Initiated first company-sponsored Phase 3 pivotal trial of uproleselan in relapsed/refractory acute myeloid leukemia (AML) at sites in U.S., Europe, C
GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2018 RESULTS ROCKVILLE, MD, MARCH 6, 2019 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the year and fourth quarter ended December 31, 2018, highlighted recent company achievements and commented on m
Read more →CBIOGLYCOMIMETICS ANNOUNCES TRANSITION PLAN FOR BOARD OF DIRECTORS · Current Board Member Tim Pearson to become Board Chair effective at the close of the company's annual meeting on
GLYCOMIMETICS ANNOUNCES TRANSITION PLAN FOR BOARD OF DIRECTORS ROCKVILLE, MD, March 5, 2019 GlycoMimetics, Inc. (Nasdaq: GLYC) announced today planned transitions within the company's Board of Directors. Current Board Chair Jim Barrett, who has held the role since the company's
Read more →CBIOSCOTT JACKSON, VETERAN BIOPHARMACEUTICAL EXECUTIVE
SCOTT JACKSON, VETERAN BIOPHARMACEUTICAL EXECUTIVE, JOINS GLYCOMIMETICS BOARD OF DIRECTORS ROCKVILLE, MD, November 28, 2018 GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that it has appointed Scott Jackson, former Chief Executive Officer of Celator Pharmaceuticals, Inc., to
Read more →CBIOGLYCOMIMETICS REPORTS THIRD QUARTER 2018 RESULTS AND HIGHLIGHTS RECENT COMPANY ACHIEVEMENTS · Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for
GLYCOMIMETICS REPORTS THIRD QUARTER 2018 RESULTS AND HIGHLIGHTS RECENT COMPANY ACHIEVEMENTS ROCKVILLE, MD, November 2, 2018 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2018 and highlighted recent company achie
Read more →CBIOGLYCOMIMETICS REPORTS SECOND QUARTER 2018 RESULTS AND HIGHLIGHTS RECENT COMPANY ACHIEVEMENTS · Announced a Cooperative Research and Development Agreement (CRADA) to collaborate with the National Cancer Institute (NC
GLYCOMIMETICS REPORTS SECOND QUARTER 2018 RESULTS AND HIGHLIGHTS RECENT COMPANY ACHIEVEMENTS ROCKVILLE, MD, August 9, 2018 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the second quarter ended June 30, 2018 and highlighted recent company achievemen
Read more →CBIOInnovation Today, Healing Tomorrow. July 2018 CORPORATE OVERVIEW NASDAQ: GLYC GlycoMimetics, Inc. To the extent that statements contained in this presentation are not descriptions of historical facts regarding GlycoMimet
Data Flow of Major Anticipated Announcements Q3 2018 GMI-1271 (Uproleselan): Initiation of GMI-sponsored Phase 3 registration trial in R/R AML Q1 2019 GMI-1271(Uproleselan): Initiation of NCI and HOVON consortium-funded AML trials in frontline populations Rivipansel enrollment co
Read more →CBIOGLYCOMIMETICS REPORTS FIRST QUARTER 2018 RESULTS · Based on guidance from the US Food and Drug Administration (FDA), announced study design for GlycoMimetics-sponsored Phase 3 trial of candidate GMI-1271 in relapsed
GLYCOMIMETICS REPORTS FIRST QUARTER 2018 RESULTS ROCKVILLE, MD, MaY 3, 2018 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2018 and highlighted recent company achievements. Quarter-end cash as a result of a follow-on
Read more →CBIOGlycoMimetics Announces Proposed Public Offering of Common Stock ROCKVILLE, Md. (BUSINESS WIRE)
GlycoMimetics Announces Proposed Public Offering of Common Stock ROCKVILLE, Md. (BUSINESS WIRE) Mar. 19, 2018 GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it
Read more →CBIOGLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2017 RESULTS · In an oral presentation of data from its Phase 1/2 AML trial of GMI-1271 at the American Society of Hematology Annual Meeting (ASH), GlycoMimetics rep
GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2017 RESULTS ROCKVILLE, MD, MARCH 6, 2018 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2017. Highli
Read more →CBIOGLYCOMIMETICS REPORTS PROGRAM UPDATES AND THIRD QUARTER 2017 RESTULTS - Ongoing discussions with U.S. Food and Drug Administration (FDA) regarding regulatory path for GMI-1271, including planned Phase 3 trial initiation
GLYCOMIMETICS REPORTS PROGRAM UPDATES AND THIRD QUARTER 2017 RESTULTS ROCKVILLE, MD, November 8, 2017 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the third quarter and nine months ended September
Read more →CBIOGLYCOMIMETICS REPORTS PROGRAM UPDATES AND SECOND QUARTER 2017 RESTULTS · FDA granted Breakthrough Therapy designation to the Company's drug candidate, GMI-1271, for treatment of adults with relapsed/refractory acute
GLYCOMIMETICS REPORTS PROGRAM UPDATES AND SECOND QUARTER 2017 RESTULTS ROCKVILLE, MD, august 3, 2017 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the second quarter ended June 30, 2017. In the sec
Read more →CBIOGLYCOMIMETICS
GLYCOMIMETICS APPOINTS BOSTON BIOMEDICAL CEO PATRICIA S. ANDREWS TO ITS BOARD OF DIRECTORS ROCKVILLE, MD, June 12, 2017 GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Patricia S. Andrews, chief executive officer and director of Boston Biomedical, Inc., to
Read more →CBIOUnless the context otherwise requires, we use the terms GlycoMimetics, the Company, we, us and our in this Current Report on Form 8-K, or this Report, to refer to GlycoMimetics, Inc., a Delaware corporation. GlycoMimetic
Unless the context otherwise requires, we use the terms GlycoMimetics, the Company, we, us and our in this Current Report on Form 8-K, or this Report, to refer to GlycoMimetics, Inc., a Delaware corporation. GlycoMimetics, the GlycoMimetics logo and other trademarks or service ma
Read more →CBIOGLYCOMIMETICS REPORTS PROGRAM UPDATES AND FIRST QUARTER 2017 RESULTS · Completed enrollment in the first of two patient cohorts in the Phase 1/2 acute myeloid leukemia (AML) trial of GMI-1271 · Presented precli
GLYCOMIMETICS REPORTS PROGRAM UPDATES AND FIRST QUARTER 2017 RESULTS ROCKVILLE, MD, MaY 8, 2017 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the first quarter ended March 31, 2017. In the first qu
Read more →CBIOGLYCOMIMETICS APPOINTS SCOTT KOENIG OF MACROGENICS
GLYCOMIMETICS APPOINTS SCOTT KOENIG OF MACROGENICS TO BOARD OF DIRECTORS Two Long-Time Board Members to Step Down After Company's 2017 Annual Meeting ROCKVILLE, MD, March 13, 2017 GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Scott Koenig, M.D., Ph.D.,
Read more →CBIOGLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2016 RESULTS
GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2016 RESULTS ROCKVILLE, MD, March 1, 2017 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2016. In 2016
Read more →CBIOGLYCOMIMETICS REPORTS THIRD QUARTER 2016 RESULTS AND PROGRESS IN CLINICAL DEVELOPMENT
GLYCOMIMETICS REPORTS THIRD QUARTER 2016 RESULTS AND PROGRESS IN CLINICAL DEVELOPMENT ROCKVILLE, MD, November 4, 2016 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the quarter ended September 30, 201
Read more →CBIOGLYCOMIMETICS reports second quarter 2016 results ROCKVILLE, MD
GLYCOMIMETICS reports second quarter 2016 results ROCKVILLE, MD, August 4, 2016 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter and six months ended June 30, 2016. For GlycoMimetics, the second quarter was highlighted by both financial
Read more →CBIOUnless the context otherwise requires, we use the terms “GlycoMimetics,” the “Company,” “we,” “us” and “our” in this Current Report on Form 8-K, or th
Unless the context otherwise requires, we use the terms GlycoMimetics, the Company, we, us and our in this Current Report on Form 8-K, or this Report, to refer to GlycoMimetics, Inc., a Delaware corporation. GlycoMimetics,'' the GlycoMimetics logo and other trademarks or service
Read more →CBIOThe treatment of patients with relapsed or refractory acute myeloid leukemia (AML) remains a significant challenge with poor outcomes primarily due to low remission rates as well as short remission duration. Although cyt
MEO and PSB receive research funding from GlycoMimetics, Inc. JLM and HMT are employees of and have equity ownership in GlycoMimetics, Inc. Funding of this trial : GlycoMimetics, Inc. ClinicalTrials.gov Identifier: NCT02306291 For further information please contact hthackray@glyc
Read more →CBIOGLYCOMIMETICS REPORTS FIRST QUARTER 2016
GLYCOMIMETICS REPORTS FIRST QUARTER 2016 RESULTS ROCKVILLE, MD, May 4, 2016 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2016. In February of 2016, we announced the topline readout of data from the first two cohorts i
Read more →CBIOGLYCOMIMETICS APPOINTS IMMUNOGEN CEO Daniel Junius TO BOARD OF DIRECTORS Gaithersburg, MD, March 21 , 2016 – GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Dire
GLYCOMIMETICS APPOINTS IMMUNOGEN CEO Daniel Junius TO BOARD OF DIRECTORS Gaithersburg, MD, March 21, 2016 GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a mem
Read more →CBIOGLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2015
GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2015 RESULTS ROCKVILLE, MD, February 29, 2016 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the fourth quarter and year ended December 31, 2015. As of December 31, 2015, GlycoMimetics had cash and cash e
Read more →CBIOGLYCOMIMETICS reports THIRD quarter 2015 results ROCKVILLE, MD, November 12 , 2015 – GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the third quarter ended
GLYCOMIMETICS reports THIRD quarter 2015 results ROCKVILLE, MD, November 12, 2015 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the third quarter ended September 30, 2015. As of September 30, 2015, GlycoMimetics had cash and cash equivalents of $53.8 mi
Read more →CBIOGLYCOMIMETICS REPORTS SECOND QUARTER 2015
GLYCOMIMETICS REPORTS SECOND QUARTER 2015 RESULTS ROCKVILLE, MD, August 6, 2015 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter ended June 30, 2015. As of June 30, 2015, GlycoMimetics had cash and cash equivalents of $40.2 million. Gly
Read more →CBIOGLYCOMIMETICS REPORTS FIRST QUARTER 2015
GLYCOMIMETICS REPORTS FIRST QUARTER 2015 RESULTS GAITHERSBURG, MD, May 5, 2015 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended GlycoMimetics used the first quarter to focus on development activities, primarily preparing to initiat
Read more →CBIOGLYCOMIMETICS PROVIDES UPDATE ON PFIZER S PLANS TO INTITIATE PHASE 3 TRIAL WITH RIVIPANSEL IN MID-2015 GlycoMimetics to receive $20 million milestone payment upon dosing of first patient in trial GAITHERSBURG, MD, APRIL
GLYCOMIMETICS PROVIDES UPDATE ON PFIZER S PLANS TO INTITIATE PHASE 3 TRIAL WITH RIVIPANSEL IN MID-2015 GlycoMimetics to receive $20 million milestone payment upon dosing of first patient in trial GAITHERSBURG, MD, APRIL 7, 2015 GlycoMimetics, Inc. (NASDAQ: GLYC) announced toda
Read more →CBIOGLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2014 RESULTS Year-End Cash and Cash Equivalents of $55.2 million GAITHERSBURG, MD
GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2014 RESULTS Year-End Cash and Cash Equivalents of $55.2 million GAITHERSBURG, MD, March 16, 2015 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the fourth quarter and year ended December 31, 2014. As o
Read more →CBIOGLYCOMIMETICS REPORTS THIRD QUARTER 2014
GLYCOMIMETICS REPORTS THIRD QUARTER 2014 RESULTS GAITHERSBURG, MD, October 31, 2014 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the third quarter ended September 30, 2014. As of September 30, 2014, GlycoMimetics had cash and cash equivalents of $61.4
Read more →CBIOGLYCOMIMETICS ANNOUNCES A DELAY IN THE INITIATION OF THE PHASE 3
GLYCOMIMETICS ANNOUNCES A DELAY IN THE INITIATION OF THE PHASE 3 TRIAL September 26, 2014 GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it has been informed by Pfizer (NYSE: PFE), the company responsible for ongoing clinical development of rivipansel, that initiation o
Read more →CBIOGLYCOMIMETICS REPORTS SECOND QUARTER 2014
GLYCOMIMETICS REPORTS SECOND QUARTER 2014 RESULTS GAITHERSBURG, MD, July 31, 2014 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter ended June 30, 2014. As of June 30, 2014, GlycoMimetics had cash and cash equivalents of $66.2 million, w
Read more →CBIOSource: GlycoMimetics Contact: Brian Hahn Email: bhahn@glycomimetics.com Phone: 240-243-1207 GLYCOMIMETICS APPOINTS MARK A. GOLDBERG, M.D. TO BOARD OF DIRECTORS - Dr. Goldberg Brings Perspective as Medical Oncologist and
GLYCOMIMETICS APPOINTS MARK A. GOLDBERG, M.D. TO BOARD OF DIRECTORS - Dr. Goldberg Brings Perspective as Medical Oncologist and Hematologist and Extensive Biopharmaceutical Regulatory Experience to GlycoMimetics Board - GAITHERSBURG, MD, July 10, 2014 GlycoMimetics, Inc. (NASD
Read more →CBIOGLYCOMIMETICS REPORTS FIRST QUARTER 2014
GLYCOMIMETICS REPORTS FIRST QUARTER 2014 RESULTS GAITHERSBURG, MD, May 8, 2014 GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2014. As of March 31, 2014, GlycoMimetics had cash and cash equivalents of $57.0 million, whi
Read more →CBIO31/2014 GlycoMimetics Reports Fourth Quarter and Year-End 2013 Results GAITHERSBURG, Md. (BUSINESS WIRE) GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the fourth quarter and year ended
Reports Fourth Quarter and Year-End 2013 Results GAITHERSBURG, Md. (BUSINESS WIRE) GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the fourth quarter and year ended December 31, 2013. In its initial public offering completed in January 2014, GlycoMimet
Read more →Competitive Position
How CBIO ranks across every disease it competes inCompetitive Position is a premium feature
See how CBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial